<?php
	// $pageTitle = "Page Title";
	// $description = "Description text here";
	// $keywords = "Keywords here";
	// $activePage = "home";
	
	include("includes/header.php");
?>
<style>
  
    
    .diff1stback {
  background-image: url("assets/images/background1.jpg");
  height: 1260px;
  width: 100%;
  }
  
 .whiteback {
       float: left;
    background-image: url(assets/images/diffrenciation/1.png);
    
      height:800px ;
  
    background-size: 100% 
   
    
  
  }
.whiteback1 {
      margin-top:0px;
    background-image: url(assets/images/diffrenciation/5.png);
    height:397px;
    margin-left:100px;
    background-size: 93%;
    relative: position;
    left: 93px;
    background-repeat: no-repeat;
    
  
 }
 .whiteback1 h2{text-align:left;color:#d40072;
     
         

 }




</style>


        
<div class="container-fluid no-padding">

 <div class="diff1stback" style="margin-top:-15px;">
    <div class="col-md-12 whiteback">
        <h2 style="color:#580f8b; margin-top:68px;margin-left:60px;line-height: 1.4;font-size: 46px;font-family: politica;  ">XERAVA: THE FIRST FULLY SYNTHETIC <br>FLUOROCYCLINE ANTIBACTERIAL<sup>1,2</sup></h2>
         <h4 style="color: #d40072;margin-left:60px;     font-size: 26px; margin-top:25px;
         font-weight: 500;
         line-height: 33px;font-family: Acuminbold; ">Key structural modifications to the tetracycline core differentiate XERAVA from  <br>tigecycline2</h4>
    <p style="color:#4c4c4c;margin-left:60px; font-weight:bold;font-size:23px;line-height:27px; margin-top:15px; font-family:">• The C7 and C9 substitutions are not present in any naturally occurring or semisynthetic <br> tetracyclines and the substitution pattern imparts microbiologic activities including <br>in vitro activity against Gram-positive and Gram-negative strains expressing certain <br>tetracycline-specific resistance mechanisms1 
</p>
        <p style="color:#4c4c4c;margin-left:60px; font-weight:bold;font-size:23px;line-height:27px; margin-top:0px; ">
        <br> • Retains activity against certain tetracycline resistance mechanisms<sup>1</sup></p>
        <p style="color:#4c4c4c;margin-left:60px; font-weight:bold;font-size:23px;line-height:27px; margin-top:0px;text-indent:10px; ">   — Efflux mediated by <i>tet</i>(A), <i>tet</i>(B),</i> and <i>tet</i>(K)</p>
        <p style="color:#4c4c4c;margin-left:60px; font-weight:bold;font-size:23px;line-height:27px; margin-top:0px;text-indent:10px; ">   — Ribosomal protection as encoded by <i>tet</i>(M) and <i>tet</i>(Q) </p>
        <p style="color:#4c4c4c;margin-left:60px; font-weight:bold;font-size:23px;line-height:27px; margin-top:0px; "><br>• XERAVA was 2- to 4-fold more potent than tigecycline in vitro against Gram-positive<br>and Gram-negative bacteria, and 2- to 8-fold more potent against most anaerobes<sup>2</sup> 
        <br> <br>• Low rates of nausea (6.5%) and vomiting (3.7%)<sup>1</sup> </p>
     </div>
    <div class="col-md-12 whiteback1 pull-right">
      <h4 style="color:#d40072;margin-left:216px;margin-top:50px;font-size:22px;">An evolution in tetracycline structure<sup>1,3</sup></h4>
      
      <h2 class="headyellow" style="color:#d40072;margin-left:360px;margin-top:245px;font-family: politica;font-size:26px;">XERAVA<span style="color:#413f42;margin-left:422px;font-size: 26px;" class="tigerline">TIGECYCLINE</span></span>
            </div>   
 </div>
</div>
<section>
 <div class="container-fluid graph" style="background-image: url(assets/images/diffrenciation/3.png); background-size:100% ; height:718px;" >
     <div style="margin-left:60px;"><br>
     <h2 style="color:#580f8b;margin-top:50px;   font-family: politica;">RETAINS ACTIVITY AGAINST CERTAIN TETRACYCLINE-SPECIFIC <br>RESISTANCE MECHANISMS<sup>4</sup></h2>
    <p style="color:#d40072;margin-top:40px;margin-bottom:19px; font-family: Acuminbold;    font-size: 20px;">XERAVA in vitro activity: tetracycline-specific resistance genotypes</p>
 </div> 
    <div class="container">
    <img src="assets/images/diffrenciation/4.png" class="img-fluid" alt="Responsive image" style="width:100%;">
    </div>
    <p style="color:#4c4c4c;font-weight:600px; ;margin-left:103px; margin-top:5px; font-weight: bold;">In vitro activity does not necessarily correlate with clinical efficacy.  </p>
                                                                                                                                 </p>
 </div>
 </section>

 <section>
     <div class="container-fluid" style="background-image: url(assets/images/diffrenciation/6.jpg); background-size:100% ; height:180px; ">
             <h2 style="color:white;text-align:center;margin-top:45px; margin-bottom:20px;font-family: politica;">PROVEN AS EFFECTIVE AS CARBAPENEMS IN PATIENTS WITH CIAI<sup>1,5</sup></h2>
             <button type="button" class="btn btn-danger mybutton ">VIEW EFFICANCY RESULTS</button>
             
     </div>
 </section>


 
<style>
    .mybutton {
     background: none;
    color: white;
    border: 1px solid white;
    border-radius: 20px;
    outline: none;
    margin-left: 44%;
    margin-top: 10px;
	font-family:Acuminbold;

}
button.btn.btn-danger.mybutton {
  outline: none;
}
    </style>
    

    <section id="our-department" class="our-department">
            <div class="container">
            
                <div class="row">
                    <div class="">
                     
                        <div class="tab-content tab-content col-sm-12 col-md-12  no-padding">
                            <div class="tab-pane active" id="CARDIOLOGY">
                                <div class="tab-image">
                                        <p class="" style="font-size:16px;font-family:Acuminpro;font-weight:500;">
                                                MIC, minimum inhibotory concentration</p><br>   
                                                <p style="font-size:14px;font-family:Acuminpro;font-weight:500;"><b>References: 1.</b> XERAVA [prescribing information]. Watertown, MA: Tetraphase Pharmaceuticals, Inc.; 2018.<b> 2.</b> Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. <i>Drugs.</i> 2016;76:567-588. <b>3.</b> Tygacil [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2018. <b>4.</b> Grossman TH, Starosta AL, Fyfe C, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. <i>Antimicrob Agents Chemother.</i> 2012;56(5):2559-2564. <b>5.</b> National Institutes of Health. US National Library of Medicine. Efficacy and safety study of eravacycline compared with ertapenem in complicated intra-abdominal infections (IGNITE1). Clinicaltrials.gov website. Updated March 21, 2016. https://clinicaltrials.gov/ct2/show/NCT01844856?term=IGNITE+eravacycline&rank=1. Accessed July 26, 2018.</p><br><br><br><br>
                                  <p class="blue">
                                       Indications and Usage </p>
                                
                                    <p class="italic">XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: <i>Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium<br> Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in<br> patients</i> 18 years or older.</p><br>
									<p><u>Limitations of Use</u></p>
									<p>
XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI).</p><br>
<p class="blue">Usage</p>
<p class="">To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should <br>be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data,<br> local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p><br>
<p class="blue">Important Safety Information</p>
<p>XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. <br>Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.</p><br>
<p>The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. </p><br>
<p>The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.</p><br>
<p><i>Clostridium difficile </i>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, and may range in severity from <br>mild diarrhea to fatal colitis. </p><br>
<p>The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions (7.7%), nausea (6.5%), and <br>vomiting (3.7%). </p><br>
<p>XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti-anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA.  Discontinue XERAVA if any of these adverse reactions are suspected.</p><br>
<p><b>To report SUSPECTED ADVERSE REACTIONS, contact Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</b></p> 
                            </div>
                       
                      
                        </div>
                    </div>
                    <!-- tab content -->
                </div>
            </div>
        </section>


            




     <?php
	// $pageTitle = "Page Title";
	// $description = "Description text here";
	// $keywords = "Keywords here";
	// $activePage = "home";
	
	include("includes/footer.php");
?>